Therapeutic Effect of HDAC5 Binding and Cell Penetrating Peptide for the Treatment of Inflammatory Bowel Disease

被引:1
作者
Kim, Deogil [1 ]
Lee, Dong Woo [1 ,2 ,3 ]
Yoon, Gookjin [2 ,3 ]
Jeong, Eui Kyun [1 ]
Choi, Moon Sil [1 ]
Lee, Hoo Cheol [1 ]
Park, Yoon Shin [4 ]
Chung, Chong Pyung [1 ]
Lee, Jue-Yeon [1 ]
Park, Yoon Jeong [1 ,2 ,3 ]
机构
[1] Nano Intelligent Biomed Engn Corp NIBEC, Res Inst, Seoul 03127, South Korea
[2] Seoul Natl Univ, Dent Res Inst, Sch Dent, 403 Biomat Res Bldg,101 Daehak Ro, Seoul 03080, South Korea
[3] Seoul Natl Univ, Dept Dent Regenerat Biotechnol, 403 Biomat Res Bldg,101 Daehak Ro, Seoul 03080, South Korea
[4] Chungbuk Natl Univ, Coll Nat Sci, Sch Biol Sci, Dept Biol Sci & Biotechnol, Cheongju 28644, South Korea
基金
新加坡国家研究基金会;
关键词
Cell-penetrating peptide; Anti-inflammatory agent; Inflammatory bowel disease; Macrophage; Histone deacetylase; JANUS KINASE INHIBITOR; HUMAN BETA-DEFENSIN-3; TOFACITINIB; ANTIBODY; IMMUNE; DOMAIN; AZATHIOPRINE; PREVALENCE; DEFENSINS; MECHANISM;
D O I
10.1007/s13770-023-00572-7
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background:Inflammatory bowel disease (IBD) is an incurable disease that negatively influences the quality of life of patients. Current and emerging therapies target proinflammatory cytokines and/or receptors to downregulate proinflammatory responses, but insufficient remission requires other therapeutic agents. Herein, we report that the synthetic anti-inflammatory peptide 15 (SAP15) is capable of cell penetration and anti-inflammatory activity in human macrophages.Methods:SAP15 was labeled with fluorescence and administered to human leukemia monocytic cells (THP-1) cells for cell penetration analysis. Using biolayer interferometry analysis, the binding affinity of SAP15 with histone deacetylase 5 (HDAC5) was measured. SAP15-treated THP-1 cells were analyzed by protein phosphorylation assay, flow cytometry, and enzyme-linked immunosorbent assay (ELISA). In addition, in vivo analysis of the therapeutic effect on IBD was observed in a dextran sulfate sodium (DSS)-induced model. Samples from SAP15-treated mice were analyzed at both the macroscopic and microscopic levels using ELISA, myeloperoxidase (MPO) assays, and histological evaluations.Results:SAP15 was internalized within the cytosol and nucleus of THP-1 cells and bound to the HDAC5 protein. SAP15-treated macrophages were assessed for protein phosphorylation and showed inhibited phosphorylation of HDAC5 and other immune-related proteins, which led to increased M2-like macrophage markers and decreased M1-like macrophage markers and tumor necrosis factor-& alpha; and interleukin-6 cytokine levels. The SAP15 treatment on IBD model showed significant recovery of colon length. Further histological analysis of colon demonstrated the therapeutic effect of SAP15 on mucosal layer. Moreover, proinflammatory cytokine levels and MPO activity from the plasma show that SAP15 is effective in reduced proinflammatory responses.Conclusion:These findings suggest that SAP15 is a novel peptide with a novel cell-penetrating peptide with anti-inflammatory property that can be used as a therapeutic agent for IBD and other inflammatory diseases.
引用
收藏
页码:965 / 979
页数:15
相关论文
共 62 条
  • [41] Infliximab in inflammatory bowel disease
    Papamichael, Konstantinos
    Lin, Steve
    Moore, Matthew
    Papaioannou, Garyfallia
    Sattler, Lindsey
    Cheifetz, Adam S.
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2019, 10
  • [42] Cell-penetrating peptide sequence and modification dependent uptake and subcellular distribution of green florescent protein in different cell lines
    Patel, Sanjay G.
    Sayers, Edward J.
    He, Lin
    Narayan, Rohan
    Williams, Thomas L.
    Mills, Emily M.
    Allemann, Rudolf K.
    Luk, Louis Y. P.
    Jones, Arwyn T.
    Tsai, Yu-Hsuan
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [43] Molecular and epigenetic basis of macrophage polarized activation
    Porta, Chiara
    Riboldi, Elena
    Ippolito, Alessandro
    Sica, Antonio
    [J]. SEMINARS IN IMMUNOLOGY, 2015, 27 (04) : 237 - 248
  • [44] Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH2) with anti-inflammatory activity in the mouse models of colitis
    Salaga, M.
    Binienda, A.
    Draczkowski, P.
    Kosson, P.
    Kordek, R.
    Jozwiak, K.
    Fichna, J.
    [J]. PEPTIDES, 2018, 108 : 34 - 45
  • [45] Sandborn William J, 2016, Gastroenterol Hepatol (N Y), V12, P438
  • [46] A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease
    Sandborn, William J.
    Ghosh, Subrata
    Panes, Julian
    Vranic, Ivana
    Wang, Wenjin
    Niezychowski, Wojciech
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (09) : 1485 - U366
  • [47] Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
    Sandborn, William J.
    Ghosh, Subrata
    Panes, Julian
    Vranic, Ivana
    Su, Chinyu
    Rousell, Samantha
    Niezychowski, Wojciech
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (07) : 616 - 624
  • [48] JAK inhibition as a therapeutic strategy for immune and inflammatory diseases (vol 16, pg 843, 2017)
    Schwartz, Daniella M.
    Kanno, Yuka
    Villarino, Alejandro
    Ward, Michael
    Gadina, Massimo
    O'Shea, John J.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (01) : 78 - 78
  • [49] Mammalian defensins in the antimicrobial immune response
    Selsted, ME
    Ouellette, AJ
    [J]. NATURE IMMUNOLOGY, 2005, 6 (06) : 551 - 557
  • [50] Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes
    Shibata, Hiroko
    Nishimura, Kazuko
    Miyama, Chizuru
    Tada, Minoru
    Suzuki, Takuo
    Saito, Yoshiro
    Ishii-Watabe, Akiko
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2018, 452 : 73 - 77